Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

The collaboration reflects Ebn Sina Medical’s commitment to delivering high-quality medicinal products to the local market, ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

Beigene (NASDAQ:ONC – Free Report) had its target price raised by JPMorgan Chase & Co. from $311.00 to $317.00 in a report published on Monday,Benzinga reports.JPMorgan Chase & Co. currently has ...

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET. Summit ...

There are four emerging powerhouses in China biotech: Henlius, BeiGene, Innovent and ZaiLab. All were founded in the 2010s, ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...

We’ve lowered our fair value estimate of Snap-on stock. We sell different types of products and services to both investment professionals and individual investors. These products and services ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer ...